Results of a randomized, placebo-controlled, first-in-human trial of topical CY-002 in patients with cutaneous warts.

1 October 2022. doid: 10.1111/jdv.18291

Pagan L, Yfanti C, Rijneveld R, Todd M, Jongste P, Feijen JJ, Klaassen ES, Bouwes Bavinck JN, Struijk L, de Koning MNC, Prestegarden L, Niemeyer-van der Kolk T, van Poelgeest MIE, Rissmann R